FGF23 and secondary hyperparathyroidism: According to Haffner et al., conventional therapy with oral phosphate and active vitamin D analogues (calcitriol or alfacalcidol) remains essential to enhance phosphate absorption and suppress secondary hyperparathyroidism, yet it does not address the primary FGF23-driven mechanism.